UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
For
the month of October 2025
Commission
File Number: 001-41937
Psyence
Biomedical Ltd.
(Translation
of registrant’s name into English)
121
Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒
Form 20-F ☐ Form 40-F
Explanatory
Note
Psyence Biomedical Ltd (the “Company”) announced that Dr. Neil Maresky has transitioned from his role as Chief Executive Officer
and Director of Psyence Biomedical Ltd. to serve as the Company’s Global Head, Clinical Development, where he will lead the Company’s
global clinical development initiatives, including its Phase 2b clinical trial in Australia.
In
connection with this transition, the Company’s Chairman, Mr. Jody Aufrichtig, has assumed the role of Chief Executive Officer
and will oversee Nasdaq-related and corporate operations. The vacancy on the Board resulting from Dr. Maresky’s transition
will be filled either by way of a vote of a quorum of Directors or at the Company’s next annual general meeting of
shareholders, in accordance with applicable law and the Company’s governing documents.
Incorporation
by Reference
The
information contained in this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement
on Form F-3 (File No. 333-285542), and any prospectuses or prospectus supplements filed pursuant thereto.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Dated:
October 9, 2025
Psyence Biomedical Ltd. |
|
|
|
|
By: |
/s/ Warwick
Corden-Lloyd |
|
Name: |
Warwick Corden-Lloyd |
|
Title: |
Chief Financial Officer
|
|